{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,6,27]],"date-time":"2026-06-27T04:45:38Z","timestamp":1782535538788,"version":"3.54.5"},"reference-count":31,"publisher":"SAGE Publications","issue":"4","license":[{"start":{"date-parts":[[2025,9,6]],"date-time":"2025-09-06T00:00:00Z","timestamp":1757116800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/journals.sagepub.com\/page\/policies\/text-and-data-mining-license"}],"content-domain":{"domain":["journals.sagepub.com"],"crossmark-restriction":true},"short-container-title":["Journal of Pharmacy Practice"],"published-print":{"date-parts":[[2026,8]]},"abstract":"<jats:p>Olmesartan, an angiotensin II receptor blocker (ARB) approved in 2002, is used to treat hypertension, either alone or with other antihypertensive drugs. It has been frequently associated with sprue-like enteropathy, while few cases of colitis have been reported. Differentiating between sprue-like enteropathy and colitis is of clinical concern, since just the first condition is a well-documented adverse event of olmesartan. Diagnosis of these occurrences is difficult, as symptoms are unspecific namely diarrhoea, weight loss, fatigue, nausea, and abdominal discomfort, with laboratory findings showing anaemia, electrolyte imbalances, and vitamin deficiencies. Here, we report two cases of patients in treatment for hypertension with olmesartan in association with hydrochlorothiazide and amlodipine, who developed sprue-like enteropathy and colitis, respectively. We then conducted a disproportionality analysis of cases retrieved from the Food and Drug Administration (FDA) Adverse Event Reporting System (FAERS) to assess the association level between these conditions and olmesartan. We found a strong association between olmesartan and sprue-like enteropathy (ROR 8499.53 (95% CI: 8402.05 \u2013 16383.99)). Olmesartan resulted to be associated also with colitis (ROR 2.56 (95% CI: 2.28 \u2013 2.88)). In light of the diagnostic challenges posed by nonspecific symptoms, these findings underscore the importance of distinguishing between the two conditions in patients exposed to olmesartan, to improve the spectrum of knowledge.<\/jats:p>","DOI":"10.1177\/08971900251376797","type":"journal-article","created":{"date-parts":[[2025,9,6]],"date-time":"2025-09-06T14:13:42Z","timestamp":1757168022000},"page":"342-347","update-policy":"https:\/\/doi.org\/10.1177\/sage-journals-update-policy","source":"Crossref","is-referenced-by-count":1,"title":["Olmesartan-Induced Enteropathy: Case Reports and Insights From FDA Adverse Event Reporting System (FAERS)"],"prefix":"10.1177","volume":"39","author":[{"ORCID":"https:\/\/orcid.org\/0009-0007-4197-6543","authenticated-orcid":false,"given":"Ilaria","family":"Mariani","sequence":"first","affiliation":[{"name":"Universit\u00e0 Degli Studi di Milano"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0000-5162-4751","authenticated-orcid":false,"given":"Giulia","family":"Mosini","sequence":"additional","affiliation":[{"name":"Universit\u00e0 Degli Studi di Milano"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-2837-5248","authenticated-orcid":false,"given":"Stefania","family":"Cheli","sequence":"additional","affiliation":[{"name":"Universit\u00e0 Degli Studi di Milano"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0004-0682-0138","authenticated-orcid":false,"given":"Sofia","family":"Dinegro","sequence":"additional","affiliation":[{"name":"Universit\u00e0 Degli Studi di Milano"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Andrea","family":"Vicenzi","sequence":"additional","affiliation":[{"name":"University Hospital Luigi Sacco"},{"name":"Universit\u00e0 Degli Studi di Milano"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Cecilia","family":"Bonino","sequence":"additional","affiliation":[{"name":"University Hospital Luigi Sacco"},{"name":"Universit\u00e0 Degli Studi di Milano"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-3513-9593","authenticated-orcid":false,"given":"Vera","family":"Battini","sequence":"additional","affiliation":[{"name":"Universit\u00e0 Degli Studi di Milano"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-4107-196X","authenticated-orcid":false,"given":"Carla","family":"Carnovale","sequence":"additional","affiliation":[{"name":"Universit\u00e0 Degli Studi di Milano"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Emilio","family":"Clementi","sequence":"additional","affiliation":[{"name":"Universit\u00e0 Degli Studi di Milano"},{"name":"Scientific Institute, IRCCS E. Medea"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sonia","family":"Radice","sequence":"additional","affiliation":[{"name":"Universit\u00e0 Degli Studi di Milano"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"179","published-online":{"date-parts":[[2025,9,6]]},"reference":[{"key":"e_1_3_5_2_2","doi-asserted-by":"publisher","DOI":"10.1161\/01.HYP.0000107251.49515.c2"},{"key":"e_1_3_5_3_2","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(23)02277-8"},{"key":"e_1_3_5_4_2","doi-asserted-by":"publisher","DOI":"10.1002\/pds.4402"},{"key":"e_1_3_5_5_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.dld.2015.09.014"},{"key":"e_1_3_5_6_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.mayocp.2012.06.003"},{"key":"e_1_3_5_7_2","unstructured":"U.S. Food and Drug Administration (FDA). FDA Drug Safety Communication: FDA approves label changes to include intestinal problems (sprue-like enteropathy) linked to blood pressure medicine olmesartan medoxomil. [Internet]. https:\/\/www.fda.gov\/drugs\/drug-safety-and-availability\/fda-drug-safety-communication-fda-approves-label-changes-include-intestinal-problems-sprue"},{"key":"e_1_3_5_8_2","doi-asserted-by":"publisher","DOI":"10.1007\/s12328-021-01514-3"},{"key":"e_1_3_5_9_2","doi-asserted-by":"publisher","DOI":"10.1186\/s12876-021-01926-y"},{"key":"e_1_3_5_10_2","doi-asserted-by":"publisher","DOI":"10.1111\/apt.17855"},{"key":"e_1_3_5_11_2","doi-asserted-by":"publisher","DOI":"10.14740\/gr1301"},{"key":"e_1_3_5_12_2","author":"Angiotensin II Receptor Antagonists","year":"2017","unstructured":"Angiotensin II Receptor Antagonists. InLiverTox: Clinical and Research Information on Drug-Induced Liver Injury. National Institute of Diabetes and Digestive and Kidney Diseases. 2017.","journal-title":"LiverTox: Clinical and Research Information on Drug-Induced Liver Injury"},{"key":"e_1_3_5_13_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.jpge.2016.02.005"},{"key":"e_1_3_5_14_2","doi-asserted-by":"publisher","DOI":"10.1111\/apt.12937"},{"issue":"3","key":"e_1_3_5_15_2","first-page":"474","article-title":"What do we know today about drug-induced microscopic colitis? A case of lymphocytic colitis on olmesartan","volume":"86","author":"Djembissi Fotso A","year":"2023","unstructured":"Djembissi Fotso A, Arvanitakis M, Salame M, Gallez J, Lakis A. What do we know today about drug-induced microscopic colitis? A case of lymphocytic colitis on olmesartan. Acta Gastroenterol Belg. 2023;86(3):474-480.","journal-title":"Acta Gastroenterol Belg"},{"key":"e_1_3_5_16_2","doi-asserted-by":"publisher","DOI":"10.14740\/jocmr3047w"},{"key":"e_1_3_5_17_2","unstructured":"Fusaroli M Giunchi V. An open access toolkit for DIsproportionality ANAlysis and other pharmacovigilance investigations in the FAERS. [Internet]. 2024. Available at: https:\/\/github.com\/fusarolimichele\/DiAna_package (accessed 16 December 2024)."},{"key":"e_1_3_5_18_2","doi-asserted-by":"publisher","DOI":"10.1007\/s40264-023-01391-4"},{"key":"e_1_3_5_19_2","unstructured":"MedDRA Dictionary. [Internet]. Available at: https:\/\/www.meddra.org\/ (accessed 17 February 2025)."},{"key":"e_1_3_5_20_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.jpge.2015.12.003"},{"key":"e_1_3_5_21_2","doi-asserted-by":"publisher","DOI":"10.1093\/gastro\/goz019"},{"issue":"2","key":"e_1_3_5_22_2","first-page":"e54373","article-title":"Non-celiac enteropathy and olmesartan: an essential consideration","volume":"16","author":"Doukas SG","year":"2024","unstructured":"Doukas SG, Doukas PG, Velpari S. Non-celiac enteropathy and olmesartan: an essential consideration. Cureus. 2024;16(2):e54373.","journal-title":"Cureus"},{"key":"e_1_3_5_23_2","doi-asserted-by":"publisher","DOI":"10.1177\/10600280231191834"},{"key":"e_1_3_5_24_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.jaut.2021.102609"},{"key":"e_1_3_5_25_2","doi-asserted-by":"publisher","DOI":"10.2169\/internalmedicine.4551-24"},{"key":"e_1_3_5_26_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.humpath.2015.12.001"},{"key":"e_1_3_5_27_2","doi-asserted-by":"publisher","DOI":"10.1097\/MEG.0000000000002208"},{"key":"e_1_3_5_28_2","doi-asserted-by":"publisher","DOI":"10.3390\/diseases13070223"},{"key":"e_1_3_5_29_2","doi-asserted-by":"publisher","DOI":"10.1007\/s40264-019-00873-8"},{"key":"e_1_3_5_30_2","doi-asserted-by":"publisher","DOI":"10.1002\/deo2.142"},{"key":"e_1_3_5_31_2","doi-asserted-by":"publisher","DOI":"10.51894\/001c.6383"},{"key":"e_1_3_5_32_2","doi-asserted-by":"publisher","DOI":"10.5858\/arpa.2015-0204-RA"}],"container-title":["Journal of Pharmacy Practice"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/journals.sagepub.com\/doi\/pdf\/10.1177\/08971900251376797","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/journals.sagepub.com\/doi\/full-xml\/10.1177\/08971900251376797","content-type":"application\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/journals.sagepub.com\/doi\/pdf\/10.1177\/08971900251376797","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,6,27]],"date-time":"2026-06-27T03:56:57Z","timestamp":1782532617000},"score":1,"resource":{"primary":{"URL":"https:\/\/journals.sagepub.com\/doi\/10.1177\/08971900251376797"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,9,6]]},"references-count":31,"journal-issue":{"issue":"4","published-print":{"date-parts":[[2026,8]]}},"alternative-id":["10.1177\/08971900251376797"],"URL":"https:\/\/doi.org\/10.1177\/08971900251376797","relation":{},"ISSN":["0897-1900","1531-1937"],"issn-type":[{"value":"0897-1900","type":"print"},{"value":"1531-1937","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,9,6]]}}}